BioNTech Investor Day Presentation Deck

1 Neoantigen prediction AI & ML drive individualized cancer medicine iNeST¹ Individualized mRNA cancer vaccine Neoantigens NEO-STIM Individualized T-cell therapy Neoantigens Individualized TCR T cells Mix of shared and neoantigens 1 Partnered with Genentech. Powered by data and cutting-edge Al & ML technologies Expression Individual 3 gééén Neoantigen prediction patient samples (blood and tissue) MHC binding NORMAL Bioinformatic algorithms 2 GGGAAACTTTTTCC TUMOR GGGAAACGTTTTCC Mapping of mutations Target selection: Al and machine learning Digital & AI/ML On-demand tailored Individualized RNA manufacturing immunotherapy GOOD BINDING 5 INTERMEDIATE BINDING NO BINDING Predicted MHC Class I or Class II binding BIONTECH 38

View entire presentation